What is the quorum requirement?
A quorum of stockholders is necessary to hold a valid meeting. The presence, in person or by proxy, of the holders of
one-third in voting power of the shares of common stock and Series A Preferred Stock issued and outstanding on the record date and entitled to vote at a meeting of stockholders will constitute a quorum for the
transaction of business at the Special Meeting, provided that, with respect to the Authorized Shares Increase Proposal, at least one-third of the outstanding shares of common stock on the record date must also
be present at the Special Meeting or represented by proxy. On the record date, there were 11,049,958 shares of common stock outstanding and entitled to vote. Thus, in addition to the presence of the Series A Preferred Stock at the meeting, 3,683,320
shares of common stock must be represented by stockholders present at the Special Meeting or by proxy to have a quorum for the Authorized Shares Increase Proposal.
In addition, unless at least one-third of the outstanding shares of common stock on the record date are present at the
Special Meeting or represented by proxy, the holder of Series A Preferred Stock will not cast any votes on the Reverse Stock Split Proposal.
Your shares
will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the Special Meeting. Abstentions and
broker non-votes, if any, will be counted towards the quorum requirement. If there is no quorum, the chair of the Special Meeting or a majority of the votes present at the Special Meeting may adjourn
the meeting to another date.
How can I find out the results of the voting at the Special Meeting?
Preliminary voting results will be announced at the Special Meeting. Final voting results will be published in a current report
on Form 8-K that we expect to file no later than four business days after the conclusion of the Special Meeting. If final voting results are not available to us in time to file a Form 8-K on or before the fourth business day after the Special Meeting, we intend to file a Form 8-K to publish preliminary results and,
within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.
When are stockholder proposals and director nominations due for next years annual meeting?
To be considered for inclusion in next years annual meeting proxy materials, your proposal must be submitted in writing by March 9, 2023, to Attn:
Corporate Secretary, 3430 E. Global Loop, Tucson, Arizona 85706. If you wish to submit a proposal (including a director nomination) at the meeting that is not to be included in next years annual meeting proxy materials, you must do so between
April 19, 2023 and May 19, 2023. You are also advised to review the Companys bylaws, which contain additional requirements relating to advance notice of stockholder proposals and director nominations.
In addition to satisfying the foregoing requirements under the Companys bylaws, to comply with the universal proxy rules (once effective) stockholders
who intend to solicit proxies in support of director nominees other than our Boards nominees must provide notice that sets forth any additional information required by Rule 14a-19 promulgated under the
Securities Exchange Act of 1934, as amended (the Exchange Act). If a stockholders written notice is not received between April 19, 2023 and May 19, 2023 as specified in the immediately preceding paragraph, and does not satisfy
these additional informational requirements, the notice will not be considered properly submitted and will not be acted upon at the 2023 annual meeting of stockholders.
Whom should I contact with other questions?
If you have
additional questions about this proxy statement or the Special Meeting, or if you would like additional copies of this proxy statement, please contact: HTG Molecular Diagnostics, Inc., 3430 E. Global Loop, Tucson, Arizona 85706, Attn: Corporate
Secretary.